相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。DNA damage repair as a target in pancreatic cancer: state-of-the-art and future perspectives
Lukas Perkhofer et al.
GUT (2021)
Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021
Mary B. Daly et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)
Olaparib-mediated enhancement of 5-fluorouracil cytotoxicity in mismatch repair deficient colorectal cancer cells
Helena de Castro e Gloria et al.
BMC CANCER (2021)
Cancer genome datamining and functional genetic analysis implicate mechanisms of ATM/ATR dysfunction underpinning carcinogenesis
Erik Waskiewicz et al.
COMMUNICATIONS BIOLOGY (2021)
The role of PARP inhibitors in BRCA mutated pancreatic cancer
Jeffrey Chi et al.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2021)
The neXtProt knowledgebase in 2020: data, tools and usability improvements
Monique Zahn-Zabal et al.
NUCLEIC ACIDS RESEARCH (2020)
A Subset of Colorectal Cancers with Cross-Sensitivity to Olaparib and Oxaliplatin
Sabrina Arena et al.
CLINICAL CANCER RESEARCH (2020)
PARP inhibitors: a tsunami of indications in different malignancies
Gaelle Haddad et al.
PHARMACOGENOMICS (2020)
ATM-Deficient Cancers Provide New Opportunities for Precision Oncology
Nicholas R. Jette et al.
CANCERS (2020)
Therapeutic Potential of Combining PARP Inhibitor and Immunotherapy in Solid Tumors
Praveen Vikas et al.
FRONTIERS IN ONCOLOGY (2020)
Olaparib for Metastatic Castration-Resistant Prostate Cancer
J. de Bono et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
The DNA damage response pathway as a land of therapeutic opportunities for colorectal cancer
G. Mauri et al.
ANNALS OF ONCOLOGY (2020)
Colon Cancer: A Clinician's Perspective in 2019
Monjur Ahmed
GASTROENTEROLOGY RESEARCH (2020)
Prognostic impact of ATM mutations in patients with metastatic colorectal cancer
Giovanni Randon et al.
SCIENTIFIC REPORTS (2019)
Structural insights into the activation of ATM kinase
Jianxiong Xiao et al.
CELL RESEARCH (2019)
COSMIC: the Catalogue Of Somatic Mutations In Cancer
John G. Tate et al.
NUCLEIC ACIDS RESEARCH (2019)
Ataxia Telangiectasia Mutated Protein Loss and Benefit From Oxaliplatin-based Chemotherapy in Colorectal Cancer
Raghav Sundar et al.
CLINICAL COLORECTAL CANCER (2018)
ATM Is Required for the Repair of Oxaliplatin-Induced DNA Damage in Colorectal Cancer
Christopher J. Bakkenist et al.
CLINICAL COLORECTAL CANCER (2018)
Next-generation sequencing: recent applications to the analysis of colorectal cancer
Filippo Del Vecchio et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2017)
ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib
Chen Wang et al.
TRANSLATIONAL ONCOLOGY (2017)
The novel ATM inhibitor (AZ31) enhances antitumor activity in patient derived xenografts that are resistant to irinotecan monotherapy
Justin Greene et al.
ONCOTARGET (2017)
RECIST 1.1-Update and clarification: From the RECIST committee
Lawrence H. Schwartz et al.
EUROPEAN JOURNAL OF CANCER (2016)
A Phase I study of olaparib and irinotecan in patients with colorectal cancer: Canadian Cancer Trials Group IND 187
Eric X. Chen et al.
INVESTIGATIONAL NEW DRUGS (2016)
ATM Mutations in Cancer: Therapeutic Implications
Michael Choi et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Phase II Study of Olaparib (AZD-2281) After Standard Systemic Therapies for Disseminated Colorectal Cancer
Lawrence Leichman et al.
ONCOLOGIST (2016)
Efficiency of olaparib in colorectal cancer patients with an alteration of the homologous repair protein
Francois Ghiringhelli et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2016)
Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology
Sue Richards et al.
GENETICS IN MEDICINE (2015)
Combined olaparib and oxaliplatin inhibits tumor proliferation and induces G2/M arrest and γ-H2AX foci formation in colorectal cancer
Kaiwu Xu et al.
ONCOTARGETS AND THERAPY (2015)
PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies
J-m. Lee et al.
ANNALS OF ONCOLOGY (2014)
Hallmarks of 'BRCAness' in sporadic cancers
N Turner et al.
NATURE REVIEWS CANCER (2004)
分享论文
